Soberana 01 has been called the phase I-II clinical trial, which will validate the efficacy of the Cuban vaccine candidate. Photo: ACN.

Directors of the Finlay Vaccine Institute held a virtual meeting today with specialists from the Pan American and World Health organizations PAHO / WHO, where they discussed the progress of the Cuban vaccine candidate.

The meeting took place at the PAHO / WHO headquarters in Cuba and also had the participation of experts from the Coalition for Epidemic Preparedness Innovations (CEPI), as Carlos Fidel Martin Rodríguez, director of the National Directorate of International Economic Organizations of the Ministry of Foreign Trade and Foreign Investment (Mincex).

Soberana 01 has been called the phase I-II clinical trial that will validate the efficacy of the Cuban vaccine candidate, which began to be applied to a group of volunteers on August 24.

To do this, we work with volunteers from two population groups between 19 and 59 years old and another from 60 to 80 , to whom different doses of the drug will be applied, the research cycle comprises a term of 28 days during which four extractions are carried out. blood to patients.

The industrial strategy has been drawn up that allows for the millions of doses necessary to protect the Cuban population once the investigations have been successfully concluded.

For the specialists involved, it is a pride to have come this far, because they have been weeks of intense work, sacrifice and very tense days, in which they have counted on the intelligence and commitment of this scientific community that has as a priority taking care of health and save lifes.

The people of the largest of the Antilles are assured that they will not rest until each Cuban is protected with the vaccine against this disease, but they are reminded that at this time it is important to continue maintaining the hygienic-sanitary measures directed by the Minsap to the confrontation with COVID-19.

The Finlay Vaccine Institute has more than 30 years of experience in the development of vaccines, and the fact of having platforms developed for other epidemics, specifically for the meningitis epidemic in the 80s of the last century has allowed it to obtain these relevant results.